AML Induction Therapy: What Fellows Need to Know

Disclaimer: This article is for educational purposes only and does not constitute clinical advice. Always follow current institutional protocols and NCCN guidelines for patient care.

Why AML Induction Therapy Is High-Yield for Fellows and Boards Alike

Acute Myeloid Leukemia (AML) is the most tested hematologic malignancy on the ABIM hematology-oncology board exam — and for good reason. The management of newly diagnosed AML has transformed dramatically in the past decade, with molecular profiling now driving treatment selection at every decision point. Understanding the AML treatment algorithm is not just an exam requirement; it is a core clinical competency of modern hematologic oncology practice.

This guide walks through the key decision nodes in AML induction, from initial workup to choice of regimen, with board-exam high-yield points flagged throughout.

Step 1: Establish Diagnosis and Molecular Profile

Before any treatment decision, a complete AML workup must include:

• Bone marrow biopsy and aspirate with flow cytometry, cytogenetics (karyotype), and FISH
• Molecular panel: NPM1, FLT3-ITD/TKD, IDH1, IDH2, CEBPA, TP53, RUNX1, ASXL1, DNMT3A, TET2, and others
• CBC, BMP, LFTs, coagulation studies, uric acid, LDH
• Performance status and comorbidity assessment (key for fit vs. unfit stratification)

Board high-yield: Cytogenetics and molecular results classify patients by ELN 2022 risk (favorable, intermediate, adverse) and guide both induction choice and post-remission consolidation decisions.

Step 2: Assess Fitness for Intensive Induction

The most fundamental fork in the AML treatment algorithm is whether a patient is a candidate for intensive induction chemotherapy. There is no universally accepted definition of "fit," but key factors include:

• Age (physiologic, not chronologic)
• ECOG performance status (0–2 generally favorable)
• Cardiac function (anthracycline cardiotoxicity risk)
• Organ function (renal, hepatic)
• Presence of significant comorbidities (HCT-CI score)

Most patients under 60 with good performance status are candidates for intensive therapy. Patients over 75, or those with poor PS or significant comorbidities, are more typically directed toward lower-intensity regimens.

Step 3: Intensive Induction — The 7+3 Regimen and Its Variants

For fit patients with newly diagnosed AML, the backbone of intensive induction remains 7+3: continuous infusion cytarabine (100–200 mg/m² IV) for 7 days combined with an anthracycline (daunorubicin or idarubicin) for 3 days.

Key points about 7+3:

• Complete remission (CR) rates of approximately 60–80% in younger fit adults
• Idarubicin (12 mg/m²/day) may be preferred over daunorubicin (60–90 mg/m²/day) at many centers based on older comparative data, though more recent studies use higher daunorubicin doses
• A "day 14 bone marrow" is performed to assess response; residual blasts may prompt re-induction

CPX-351 (Vyxeos) for Secondary AML

Board high-yield: CPX-351 is a liposomal formulation of cytarabine and daunorubicin in a fixed 5:1 molar ratio, approved for therapy-related AML (t-AML) and AML with myelodysplasia-related changes (AML-MRC). The CLASSIC I trial (NCT01696084) and a pivotal Phase 3 study (Lancet 2018) demonstrated superior OS vs. 7+3 in these populations. Know when to choose CPX-351 over standard 7+3.

Step 4: Targeted Agent Additions Based on Molecular Profile

The most rapidly evolving aspect of AML induction is the addition of targeted agents to intensive or lower-intensity backbones based on actionable mutations.

FLT3-Mutated AML

Approximately 25–30% of AML cases harbor FLT3-ITD mutations (internal tandem duplication); a smaller subset have FLT3-TKD (tyrosine kinase domain) mutations. Both confer adverse prognosis, particularly FLT3-ITD with high allelic ratio.

Midostaurin (multikinase/FLT3 inhibitor) added to 7+3 induction demonstrated OS benefit in the RATIFY trial (NEJM 2017) and is now standard of care for FLT3-mutated AML in fit patients.

Quizartinib (selective FLT3-ITD inhibitor) added to 7+3 showed OS benefit in QuANTUM-First (NEJM 2023) for FLT3-ITD–positive AML and received FDA approval in 2023.

Board high-yield: Midostaurin covers both FLT3-ITD and FLT3-TKD. Quizartinib is FLT3-ITD selective.

IDH1/IDH2-Mutated AML

IDH1 and IDH2 mutations occur in approximately 6–10% and 8–13% of AML cases, respectively. They produce oncometabolite 2-hydroxyglutarate, which impairs hematopoietic differentiation.

• Enasidenib (IDH2 inhibitor): FDA-approved for relapsed/refractory IDH2-mutated AML; also studied in frontline combination
• Ivosidenib (IDH1 inhibitor): FDA-approved for R/R IDH1-mutated AML; also approved frontline in combination with azacitidine for unfit patients

Board high-yield: Differentiation syndrome is a class-effect toxicity of IDH inhibitors — recognize fever, dyspnea, pulmonary infiltrates, hypotension developing during early treatment.

Venetoclax-Based Regimens for Unfit Patients

For older or unfit patients who cannot tolerate intensive induction, venetoclax + azacitidine (Ven/Aza) has become the standard of care based on the VIALE-A trial (NEJM 2020), which demonstrated superiority over azacitidine alone in OS (14.7 vs. 9.6 months) and CR rate (36.7% vs. 17.9%).

Venetoclax is a selective BCL-2 inhibitor; azacitidine is a hypomethylating agent (HMA). The combination is highly active in NPM1-mutated and IDH1/2-mutated AML; activity is lower in TP53-mutated disease.

Board high-yield: Tumor lysis syndrome risk with venetoclax ramp-up — ensure adequate hydration and uric acid management. Also know the QTc monitoring requirements for venetoclax and CYP3A4 drug interactions (e.g., azole antifungals can raise venetoclax levels dramatically).

Step 5: ELN 2022 Risk Stratification and Post-Remission Decisions

After induction, achieving CR (or CRi), the next critical decision is post-remission consolidation. ELN 2022 risk classification drives this:

• Favorable risk (e.g., core-binding factor AML, NPM1-mutated without FLT3-ITD): High-dose cytarabine (HiDAC) consolidation × 3–4 cycles; allogeneic SCT only for MRD positivity or relapse
• Intermediate risk: Allogeneic SCT in first CR if suitable donor available, especially with FLT3-ITD co-mutation or adverse cytogenetics
• Adverse risk (e.g., TP53, RUNX1-RUNX1T1 not in CBF group, complex karyotype): Allogeneic SCT in CR1 is the standard recommendation when feasible

Key Takeaways for the Boards

• Always complete molecular profiling before choosing an AML induction regimen
• 7+3 remains the backbone for fit patients; CPX-351 is preferred for t-AML and AML-MRC
• Add midostaurin (or quizartinib for FLT3-ITD) to 7+3 in FLT3-mutated disease
• Ven/Aza is the standard for unfit patients; watch for TLS and CYP3A4 interactions
• ELN 2022 risk guides post-remission consolidation; adverse-risk patients warrant allogenic SCT in CR1
• Differentiation syndrome is a class effect of IDH inhibitors — recognize it early

References

• Döhner H, et al. Diagnosis and management of AML in adults: 2022 ELN recommendations. Blood. 2022;140(12):1345–1377.
• Stone RM, et al. Midostaurin plus chemotherapy for AML with a FLT3 mutation. NEJM. 2017;377(5):454–464.
• Erba HP, et al. Quizartinib plus chemotherapy in newly diagnosed FLT3-ITD+ AML. NEJM. 2023;388(17):1572–1581.
• DiNardo CD, et al. Venetoclax combined with decitabine or azacitidine in treatment-naive AML. Blood. 2019;133(1):7–17.
• Lancet JE, et al. CPX-351 liposome injection versus cytarabine/daunorubicin in secondary AML. J Clin Oncol. 2018;36(26):2684–2692.
• NCCN Guidelines: Acute Myeloid Leukemia — nccn.org